Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

• Status: ENROLLING_BY_INVITATION
• Trial end date: 2026-12-01

Summary

Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)

• Phase: PHASE2

Details

• Lead Sponsor: University of Cologne
• Collaborator: AstraZeneca
• Treatments: durvalumab; olaparib